Tag: Multiple myeloma

Originally co-developed by Millennium Pharmaceuticals and Janssen, the ownership and commercialization rights of the cancer drug Velcade are now split between two major pharmaceutical players. Takeda Pharmaceuticals, which acquired Millennium in 2008, handles the United States market, while Janssen Pharmaceutical Companies of Johnson & Johnson manage sales and distribution in Europe and most other parts of the world.

Approved by the FDA in 2019, selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) used to treat specific blood cancers. The generic name for this medication is selinexor, but what is selinexor also known as, and what makes its mechanism of action so unique? This article details its various names and its targeted approach to cancer treatment.

For decades, the corticosteroid dexamethasone has been a cornerstone of supportive care for patients undergoing chemotherapy. This versatile medication is used to manage a wide range of chemo-related side effects, from combating severe nausea and vomiting to reducing inflammation around tumors.

Selinexor (Xpovio), a first-in-class oral selective inhibitor of nuclear export (SINE), was granted accelerated FDA approval in 2019 for the treatment of certain hematological malignancies. But what is selinexor, and how does this innovative drug fight cancer cells?

According to the National Cancer Institute, multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. In treating this condition, one of the modern targeted therapies is SARCLISA (isatuximab), a medication designed to specifically target and eliminate cancerous cells.

According to prescribing information, the number of treatment cycles of Doxil is not fixed and depends heavily on the type of cancer, treatment response, and patient tolerability. A primary concern influencing the total number of cycles is the potential for cardiotoxicity, a risk factor shared with its parent compound, doxorubicin.

First approved by the FDA in 2013, Pomalyst (pomalidomide) is a third-generation immunomodulatory drug used to treat certain cancers, primarily multiple myeloma. This article explores the complex, multi-faceted mechanisms behind **how does the Pomalyst work** to fight cancer.

As an alkylating agent, carmustine (BCNU) interferes with cancer cell growth by damaging DNA. A primary application of what is carmustine used for is in treating specific types of brain tumors and other serious cancers, both alone and in combination with other therapies.

The typical starting dosage of dexamethasone for treating inflammation often ranges from 0.75 to 9 mg per day, making 20 mg of dexamethasone a notably high dose in many contexts. However, the definition of "a lot" is highly relative and depends entirely on the specific medical condition being treated and the duration of therapy.

First approved in the U.S. in 2008, bendamustine (brand names including Treanda and Bendeka) is a potent chemotherapy agent used to treat chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma (NHL). As an alkylating agent, it damages the DNA of cancer cells, which ultimately leads to their destruction.